Lipocine to Present at the 17th Annual Needham Healthcare Conference

SALT LAKE CITY, March 21, 2018

Lipocine Presentation Details
Date:	Wednesday, March 28th
Time: ARIVA.DE Börsen-Geflüster Kurse Lipocine 4,77 $ +1,49%	12:45pm Eastern Time
Location:	Westin Grand Central Hotel
Webcast:	http://wsw.com/webcast/needham86/lpcn/

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs: TLANDO, LPCN 1111 and LPCN 1107.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth, is currently in Phase 2 testing and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-17th-annual-needham-healthcare-conference-300616031.html

SOURCE Lipocine Inc.